User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Sflt-1 in heart failure: relation with disease severity and biomarkers

Primary tabs

Gruson, Damien [UCL] Hermans, Michel [UCL] Ferracin, Benjamin [UCL] Ahn, Sylvie [UCL] Rousseau, Michel [UCL]

(eng) Soluble fms-like tyrosine kinase-1 (sFlt-1) is an endogenous inhibitor of endothelial growth factors, such as placental growth factor (PlGF), which modulates cardiovascular (CV) remodeling. We determine sFlt-1 levels in patients with heart failure (HF) and its relationship to adverse cardiovascular (CV) events and biomarkers of cardiovascular risk. Levels of sFlt-1 and PlGF levels were also determined in healthy volunteers and patients with type 2 diabetes mellitus (T2DM). SFlt-1 and PlGF were clearly increased in HF patients in comparison to T2DM patients or healthy subjects (p < 0.01). Concentration of sFlt-1 was related to HF severity (p < 0.001) and was correlated to NT-proBNP (ρ = 0.37, p < 0.01), soluble ST2 (ρ = 0.52, p < 0.01), Galectin-3 (ρ = 0.38, p < 0.01), aldosterone (ρ = 0.25, p = 0.01) and PTH(1–84) (ρ = 0.38, p < 0.01). Furthermore, sFlt-1 levels were associated to long-term CV risk. These results suggest a potential role of sFlt-1 in HF and its potential role as biomarker of CV risk.

Document type Article de périodique (Journal article) – Article de recherche
Publication date 2016
Language Anglais
Journal information "Scandinavian Journal of Clinical & Laboratory Investigation" - Vol. 76, no. 5, p. 411-416 (2016)
Peer reviewed yes
Publisher Informa Healthcare ((United Kingdom) London)
issn 0036-5513
e-issn 1502-7686
Publication status Publié
Affiliations UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire
UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition
UCL - (SLuc) Service de biochimie médicale
UCL - (SLuc) Service d'endocrinologie et de nutrition
UCL - (SLuc) Service de cardiologie
Keywords Aldosterone ; BNP ; Galectin-3 ; ST2 ; heart failure ; prognosis sFlt-1
Links
  1. Accornero Federica, Molkentin Jeffery D., Placental Growth Factor as a Protective Paracrine Effector in the Heart, 10.1016/j.tcm.2012.05.014
  2. Accornero F., van Berlo J. H., Benard M. J., Lorenz J. N., Carmeliet P., Molkentin J. D., Placental Growth Factor Regulates Cardiac Adaptation and Hypertrophy Through a Paracrine Mechanism, 10.1161/circresaha.111.240820
  3. Andersen Louise Bjørkholt, Frederiksen-Møller Britta, Work Havelund Kathrine, Dechend Ralf, Jørgensen Jan Stener, Jensen Boye L., Nielsen Jan, Lykkedegn Sine, Barington Torben, Christesen Henrik Thybo, Diagnosis of preeclampsia with soluble Fms–like tyrosine kinase 1/placental growth factor ratio: an inter–assay comparison, 10.1016/j.jash.2014.11.008
  4. Calvier L., Miana M., Reboul P., Cachofeiro V., Martinez-Martinez E., de Boer R. A., Poirier F., Lacolley P., Zannad F., Rossignol P., Lopez-Andres N., Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis, 10.1161/atvbaha.112.300569
  5. Carnevale D., Cifelli G., Mascio G., Madonna M., Sbroggio M., Perrino C., Persico M. G., Frati G., Lembo G., Placental Growth Factor Regulates Cardiac Inflammation Through the Tissue Inhibitor of Metalloproteinases-3/Tumor Necrosis Factor- -Converting Enzyme Axis: Crucial Role for Adaptive Cardiac Remodeling During Cardiac Pressure Overload, 10.1161/circulationaha.111.050500
  6. Carnevale Daniela, Lembo Giuseppe, Placental Growth Factor and Cardiac Inflammation, 10.1016/j.tcm.2012.07.022
  7. Hochholzer W., Reichlin T., Stelzig C., Hochholzer K., Meissner J., Breidthardt T., Reiter M., Duehsler B., Freidank H., Winkler K., Twerenbold R., Mueller C., Impact of soluble fms-like tyrosine kinase-1 and placental growth factor serum levels for risk stratification and early diagnosis in patients with suspected acute myocardial infarction, 10.1093/eurheartj/ehq429
  8. Kadowaki Shinpei, Shishido Tetsuro, Honda Yuki, Narumi Taro, Otaki Yoichiro, Kinoshita Daisuke, Nishiyama Satoshi, Takahashi Hiroki, Arimoto Takanori, Miyamoto Takuya, Watanabe Tetsu, Kubota Isao, Additive clinical value of serum brain-derived neurotrophic factor for prediction of chronic heart failure outcome, 10.1007/s00380-015-0628-6
  9. Kameda Ryo, Yamaoka-Tojo Minako, Makino Akihiro, Wakaume Kazuki, Nemoto Shinji, Kitasato Lisa, Shimohama Takao, Tojo Taiki, Machida Yoji, Izumi Tohru, Soluble Fms-like Tyrosine Kinase 1 Is a Novel Predictor of Brain Natriuretic Peptide Elevation, 10.1536/ihj.54.133
  10. Kodama Yasushi, Kitta Yoshinobu, Nakamura Takamitsu, Takano Hajime, Umetani Ken, Fujioka Daisuke, Saito Yukio, Kawabata Ken-ichi, Obata Jyun-ei, Mende Akira, Kobayashi Tsuyoshi, Kugiyama Kiyotaka, Atorvastatin Increases Plasma Soluble Fms-Like Tyrosine Kinase-1 and Decreases Vascular Endothelial Growth Factor and Placental Growth Factor in Association With Improvement of Ventricular Function in Acute Myocardial Infarction, 10.1016/j.jacc.2006.03.035
  11. Ky Bonnie, French Benjamin, Ruparel Kosha, Sweitzer Nancy K., Fang James C., Levy Wayne C., Sawyer Douglas B., Cappola Thomas P., The Vascular Marker Soluble Fms-Like Tyrosine Kinase 1 Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart Failure, 10.1016/j.jacc.2011.03.032
  12. Levine Richard J., Maynard Sharon E., Qian Cong, Lim Kee-Hak, England Lucinda J., Yu Kai F., Schisterman Enrique F., Thadhani Ravi, Sachs Benjamin P., Epstein Franklin H., Sibai Baha M., Sukhatme Vikas P., Karumanchi S. Ananth, Circulating Angiogenic Factors and the Risk of Preeclampsia, 10.1056/nejmoa031884
  13. Matsumoto Takaki, Uemura Shiro, Takeda Yukiji, Matsui Masaru, Okada Sadanori, Nishida Taku, Soeda Tsunenari, Okayama Satoshi, Somekawa Satoshi, Ishigami Ken-ichi, Onoue Kenji, Kawata Hiroyuki, Kawakami Rika, Horii Manabu, Saito Yoshihiko, An Elevated Ratio of Placental Growth Factor to Soluble Fms-like Tyrosine Kinase-1 Predicts Adverse Outcomes in Patients with Stable Coronary Artery Disease, 10.2169/internalmedicine.52.9073
  14. McCurley Amy, McGraw Adam, Pruthi Dafina, Jaffe Iris Z., Smooth muscle cell mineralocorticoid receptors: role in vascular function and contribution to cardiovascular disease, 10.1007/s00424-013-1282-4
  15. McGraw A. P., Bagley J., Chen W.-S., Galayda C., Nickerson H., Armani A., Caprio M., Carmeliet P., Jaffe I. Z., Aldosterone Increases Early Atherosclerosis and Promotes Plaque Inflammation Through a Placental Growth Factor-Dependent Mechanism, 10.1161/jaha.112.000018
  16. McGraw Adam P., McCurley Amy, Preston Ioana R., Jaffe Iris Z., Mineralocorticoid Receptors in Vascular Disease: Connecting Molecular Pathways to Clinical Implications, 10.1007/s11883-013-0340-x
  17. Nakada Yasuki, Takahama Hiroyuki, Kanzaki Hideaki, Sugano Yasuo, Hasegawa Takuya, Ohara Takahiro, Amaki Makoto, Funada Akira, Yoshida Akemi, Yasuda Satoshi, Ogawa Hisao, Anzai Toshihisa, The predictability of renin–angiotensin–aldosterone system factors for clinical outcome in patients with acute decompensated heart failure, 10.1007/s00380-015-0688-7
  18. Nakamura Tomohiro, Funayama Hiroshi, Kubo Norifumi, Yasu Takanori, Kawakami Masanobu, Momomura Shin-ichi, Ishikawa San-e, Elevation of plasma placental growth factor in the patients with ischemic cardiomyopathy, 10.1016/j.ijcard.2007.10.050
  19. Nandy Debashis, Mukhopadhyay Debabrata, Basu Ananda, Both Vascular Endothelial Growth Factor and Soluble Flt-1 Are Increased in Type 2 Diabetes But Not in Impaired Fasting Glucose, 10.2310/jim.0b013e3181e96203
  20. Okamoto Yusuke, Fujita Shu-ichi, Morita Hideaki, Kizawa Shun, Ito Takahide, Sakane Kazushi, Sohmiya Koichi, Hoshiga Masaaki, Ishizaka Nobukazu, Association between circulating FGF23, α-Klotho, and left ventricular diastolic dysfunction among patients with preserved ejection fraction, 10.1007/s00380-014-0581-9
  21. Peiskerová Martina, Kalousová Marta, Danzig Vilem, Míková Blanka, Hodková Magdalena, Němeček Eduard, Bani-Hani Amjad, Ambrož David, Benáková Hana, Linhart Ales, Zima Tomas, Tesař Vladimir, Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease – a prospective observational study, 10.1186/1471-2369-14-142
  22. Rambod Mehdi, Heine Gunnar H., Seiler Sarah, Dominic Elizabeth A., Rogacev Kyrill S., Dwivedi Rama, Ramezani Ali, Wing Maria R., Amdur Richard L., Fliser Danilo, Raj Dominic S., Association of vascular endothelial factors with cardiovascular outcome and mortality in chronic kidney disease patients: A 4-year cohort study, 10.1016/j.atherosclerosis.2014.07.026
  23. Sandhofer A., Tatarczyk T., Kirchmair R., Iglseder B., Paulweber B., Patsch J.R., Schratzberger P., Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Cross-sectional data from the SAPHIR study, 10.1016/j.atherosclerosis.2009.01.031
  24. Searle J., Mockel M., Gwosc S., Datwyler S. A., Qadri F., Albert G. I., Holert F., Isbruch A., Klug L., Muller D. N., Dechend R., Muller R., Vollert J. O., Slagman A., Mueller C., Herse F., Heparin Strongly Induces Soluble Fms-Like Tyrosine Kinase 1 Release In Vivo and In Vitro--Brief Report, 10.1161/atvbaha.111.237784
  25. Shin Sanghoon, Lee Sang-Hak, Park Sungha, Kang Seok-Min, Chung Namsik, Shim Won-Heum, Cho Seung-Yun, Manabe Ichiro, Jang Yangsoo, Soluble Fms-Like Tyrosine Kinase-1 and the Progression of Carotid Intima-Media Thickness, 10.1253/circj.cj-10-0432
  26. Wollert K. C., Tailored therapy for heart failure: the role of biomarkers, 10.1093/eurheartj/ehs129
  27. Zhao Q., Ishibashi M., Hiasa K.-i., Tan C., Takeshita A., Egashira K., Essential Role of Vascular Endothelial Growth Factor in Angiotensin II-Induced Vascular Inflammation and Remodeling, 10.1161/01.hyp.0000138688.78906.6b
Bibliographic reference Gruson, Damien ; Hermans, Michel ; Ferracin, Benjamin ; Ahn, Sylvie ; Rousseau, Michel. Sflt-1 in heart failure: relation with disease severity and biomarkers. In: Scandinavian Journal of Clinical & Laboratory Investigation, Vol. 76, no. 5, p. 411-416 (2016)
Permanent URL http://hdl.handle.net/2078.1/184431